These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 29845543)

  • 1. An Industry Perspective on Dengue Drug Discovery and Development.
    Hernandez-Morales I; Van Loock M
    Adv Exp Med Biol; 2018; 1062():333-353. PubMed ID: 29845543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ten years of dengue drug discovery: progress and prospects.
    Lim SP; Wang QY; Noble CG; Chen YL; Dong H; Zou B; Yokokawa F; Nilar S; Smith P; Beer D; Lescar J; Shi PY
    Antiviral Res; 2013 Nov; 100(2):500-19. PubMed ID: 24076358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dengue Antiviral Development: A Continuing Journey.
    Low JG; Gatsinga R; Vasudevan SG; Sampath A
    Adv Exp Med Biol; 2018; 1062():319-332. PubMed ID: 29845542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in antiviral drug development towards dengue virus.
    Troost B; Smit JM
    Curr Opin Virol; 2020 Aug; 43():9-21. PubMed ID: 32795907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of Immunologically Inspired Small Molecules That Target the Viral Envelope Protein.
    Lian W; Jang J; Potisopon S; Li PC; Rahmeh A; Wang J; Kwiatkowski NP; Gray NS; Yang PL
    ACS Infect Dis; 2018 Sep; 4(9):1395-1406. PubMed ID: 30027735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dengue drug discovery: Progress, challenges and outlook.
    Lim SP
    Antiviral Res; 2019 Mar; 163():156-178. PubMed ID: 30597183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Targeted Computational Screen of the SWEETLEAD Database Reveals FDA-Approved Compounds with Anti-Dengue Viral Activity.
    Moshiri J; Constant DA; Liu B; Mateo R; Kearnes S; Novick P; Prasad R; Nagamine C; Pande V; Kirkegaard K
    mBio; 2020 Nov; 11(6):. PubMed ID: 33173007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pan-serotype antiviral to prevent and treat dengue: A journey from discovery to clinical development driven by public-private partnerships.
    Goethals O; Voge NV; Kesteleyn B; Chaltin P; Jinks T; De Marez T; Koul A; Draghia-Akli R; Neyts J; Van Loock M
    Antiviral Res; 2023 Feb; 210():105495. PubMed ID: 36567021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dengue Virus Evolution under a Host-Targeted Antiviral.
    Plummer E; Buck MD; Sanchez M; Greenbaum JA; Turner J; Grewal R; Klose B; Sampath A; Warfield KL; Peters B; Ramstedt U; Shresta S
    J Virol; 2015 May; 89(10):5592-601. PubMed ID: 25762732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The search for nucleoside/nucleotide analog inhibitors of dengue virus.
    Chen YL; Yokokawa F; Shi PY
    Antiviral Res; 2015 Oct; 122():12-9. PubMed ID: 26241002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Medicinal Chemistry of Dengue Virus.
    Behnam MA; Nitsche C; Boldescu V; Klein CD
    J Med Chem; 2016 Jun; 59(12):5622-49. PubMed ID: 26771861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological characteristics of dengue virus and potential targets for drug design.
    Qi RF; Zhang L; Chi CW
    Acta Biochim Biophys Sin (Shanghai); 2008 Feb; 40(2):91-101. PubMed ID: 18235970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dengue Virus Reporter Replicon is a Valuable Tool for Antiviral Drug Discovery and Analysis of Virus Replication Mechanisms.
    Kato F; Hishiki T
    Viruses; 2016 May; 8(5):. PubMed ID: 27164125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Potential Inhibitors for Targets Involved in Dengue Fever.
    Shanmugam A; Ramakrishnan C; Velmurugan D; Gromiha MM
    Curr Top Med Chem; 2020; 20(19):1742-1760. PubMed ID: 32552652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptides as Therapeutic Agents for Dengue Virus.
    Chew MF; Poh KS; Poh CL
    Int J Med Sci; 2017; 14(13):1342-1359. PubMed ID: 29200948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel dengue virus entry inhibitors via a structure-based approach.
    Leal ES; Aucar MG; Gebhard LG; Iglesias NG; Pascual MJ; Casal JJ; Gamarnik AV; Cavasotto CN; Bollini M
    Bioorg Med Chem Lett; 2017 Aug; 27(16):3851-3855. PubMed ID: 28668194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dengue Vaccines: A Perspective from the Point of View of Intellectual Property.
    da Veiga CP; da Veiga CR; Del Corso JM; da Silva WV
    Int J Environ Res Public Health; 2015 Aug; 12(8):9454-74. PubMed ID: 26274968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral activity of lanatoside C against dengue virus infection.
    Cheung YY; Chen KC; Chen H; Seng EK; Chu JJ
    Antiviral Res; 2014 Nov; 111():93-9. PubMed ID: 25251726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dengue Virus and Its Inhibitors: A Brief Review.
    Tian YS; Zhou Y; Takagi T; Kameoka M; Kawashita N
    Chem Pharm Bull (Tokyo); 2018; 66(3):191-206. PubMed ID: 29491253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of dengue antiviral candidates in vivo in mouse model.
    Watanabe S; Vasudevan SG
    Methods Mol Biol; 2014; 1138():391-400. PubMed ID: 24696350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.